Spike S1 Neutralizing Antibody (B.1.617.2, B.1.617.2.1, B.1.1.7, B.1.351, B.1.429, and P.1 Variants) (Clone C-A11) (SARS-CoV-2)

BPS Bioscience

Spike S1 Neutralizing Antibody (B.1.617.2, B.1.617.2.1, B.1.1.7, B.1.351, B.1.429, and P.1 Variants) (Clone C-A11) (SARS-CoV-2)

7

Neutralisation/Blocking

Research Use Only

Monoclonal

C-A11

S

surface glycoprotein

GU280_gp02; spike glycoprotein; surface glycoprotein

Rabbit

IgG

Spike glycoprotein

This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the B.1.1.7 variant, originally discovered in the U.K, and the B.1.351 variant, originally discovered in South Africa, for both the Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 spike proteins and ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (BPS Bioscience, #78018, #78133, #78152). This antibody not been tested for cross reactivity with other SARS-CoV-2 variants.

2°C to 8°C

12352203